Star source multi trade Limited (formerly Chemo Pharma Laboratories Limited) announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on February 12, 2026, at the company's registered office. The meeting commenced at 12:00 PM and concluded at 12:45 PM.

Financial Performance Overview

The company's financial performance showed significant volatility during the reporting period. The quarterly results revealed a stark contrast between Q3 FY26 and the previous quarter, with notable changes in revenue generation and profitability.

Revenue and Income Analysis

The company reported zero revenue from operations in Q3 FY26, marking a complete decline from the ₹5,256.56 thousand recorded in Q2 FY26. This represents a significant operational challenge as the company had no operational income during the quarter. Other income also remained at zero, contributing to the overall revenue decline.

Expense Structure

Despite the absence of revenue, the company incurred total expenses of ₹865.11 thousand during Q3 FY26. The major expense components included employee benefits expense of ₹216.00 thousand and administrative & other expenses of ₹649.11 thousand, while finance costs and depreciation remained at zero.

Nine-Month Performance

For the nine months ended December 31, 2025, Star Source Multitrade Limited reported revenue from operations of ₹5,256.56 thousand, entirely generated in Q2 FY26. However, the company recorded a substantial net loss of ₹117,935.62 thousand for the nine-month period, primarily driven by administrative and other expenses totaling ₹118,955.38 thousand.

Earnings Per Share

The company's earnings per share (EPS) reflected the financial challenges, with basic and diluted EPS of ₹(0.58) for Q3 FY26, compared to ₹0.65 in Q2 FY26. For the nine-month period, the EPS stood at ₹(78.62), significantly lower than ₹4.55 recorded in the corresponding period of the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors on February 12, 2026. The limited review report was prepared by S S R V & Associates, Chartered Accountants (Firm Registration No. 105017). The company operates as a single-segment entity with no subsidiary companies, maintaining a simplified corporate structure. The results were announced under Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, with the company trading under Script Id 506365 and ISIN INE320M01019.

Star Source Multitrade Limited , formerly known as Chemo Pharma Laboratories Limited, has officially announced a change in its website domain as part of its corporate rebranding initiative. The company communicated this development to the Bombay Stock Exchange on January 05, 2025, ensuring compliance with regulatory disclosure requirements.

Domain Transition Details

The company has transitioned from its previous website domain thechemopharmalaboratoriesltd.com to its new corporate domain starsourcemultitrade.com. This change reflects the company's rebranding from Chemo Pharma Laboratories Limited to Star Source Multitrade Limited.

Technical Implementation

The company has implemented a comprehensive transition strategy to ensure uninterrupted access for users. All information from the old website will be permanently redirected to the new domain, maintaining continuity of content and services. This technical approach ensures that existing users can seamlessly access the same resources previously available on the former domain.

Regulatory Compliance

The domain change notification has been made in compliance with Regulation 46 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has taken necessary steps to ensure the transition meets all regulatory requirements for listed entities.

Corporate Information

The notification was signed by Ruchit Mehta, Managing Director and Chief Executive Officer (DIN: 08810586), on behalf of Star Source Multitrade Limited. The company operates under CIN: L46900MH1942PLC003556 and maintains its listing on the Bombay Stock Exchange with Script ID 506365.